Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel

Forum Onward Medical geopend

2.169 Posts
Pagina: «« 1 ... 60 61 62 63 64 ... 109 »» | Laatste | Omlaag ↓
  1. forum rang 6 Kaviaar 10 april 2024 12:51
    Stifel Initiates Research Coverage of ONWARD® Medical with
    a Buy Rating and Target Price of EUR 12.00


    EINDHOVEN, the Netherlands — April 9, 2024 — ONWARD Medical N.V. (Euronext: ONWD),
    the medical technology company creating innovative therapies to restore movement, function,
    and independence in people with spinal cord injury (SCI), today announced that Stifel, a US-
    based full-service investment bank, has initiated coverage of ONWARD Medical with a Buy
    rating and Target Price of EUR 12.00 per share. This is a premium of 140% to the closing price
    of EUR 5.00 on April 8, 2024.

    The initiation report was published April 8, 2024. Stifel joins four other banks whose analysts
    cover ONWARD Medical, all of which maintain Buy ratings and Target Prices at substantial
    premiums to the current share price.
    “Stifel’s initiation of coverage reflects the value they place on the strategic positioning of our
    brain-computer interface (BCI) platform as well as their strong confidence in our ability to
    achieve this year’s milestones, which include the planned commercialization of our ARC-EX®
    platform later this year,” said Dave Marver, CEO of ONWARD Medical. “Stifel is the largest
    provider of global small-cap equity research, and we are gratified they recognize the value
    ONWARD can create for investors in coming quarters.”
    To learn more about ONWARD Medical’s commitment to partnering with the SCI community to
    develop innovative solutions for restoring movement, function, and independence after spinal
    cord injury, please visit ONWD.com.

    *All ONWARD Medical devices and therapies, including but not limited to ARC-IM®, ARC-EX®, ARC-
    BCI™, and ARC Therapy™, alone or in combination with a brain-computer interface (BCI), are
    investigational and not available for commercial use.
  2. forum rang 5 Stork 49 10 april 2024 16:08
    quote:

    Kaviaar schreef op 10 april 2024 12:51:

    Stifel Initiates Research Coverage of ONWARD® Medical with
    a Buy Rating and Target Price of EUR 12.00


    EINDHOVEN, the Netherlands — April 9, 2024 — ONWARD Medical N.V. (Euronext: ONWD),
    the medical technology company creating innovative therapies to restore movement, function,
    and independence in people with spinal cord injury (SCI), today announced that Stifel, a US-
    based full-service investment bank, has initiated coverage of ONWARD Medical with a Buy
    rating and Target Price of EUR 12.00 per share. This is a premium of 140% to the closing price
    of EUR 5.00 on April 8, 2024.

    The initiation report was published April 8, 2024. Stifel joins four other banks whose analysts
    cover ONWARD Medical, all of which maintain Buy ratings and Target Prices at substantial
    premiums to the current share price.
    “Stifel’s initiation of coverage reflects the value they place on the strategic positioning of our
    brain-computer interface (BCI) platform as well as their strong confidence in our ability to
    achieve this year’s milestones, which include the planned commercialization of our ARC-EX®
    platform later this year,” said Dave Marver, CEO of ONWARD Medical. “Stifel is the largest
    provider of global small-cap equity research, and we are gratified they recognize the value
    ONWARD can create for investors in coming quarters.”
    To learn more about ONWARD Medical’s commitment to partnering with the SCI community to
    develop innovative solutions for restoring movement, function, and independence after spinal
    cord injury, please visit ONWD.com.

    *All ONWARD Medical devices and therapies, including but not limited to ARC-IM®, ARC-EX®, ARC-
    BCI™, and ARC Therapy™, alone or in combination with a brain-computer interface (BCI), are
    investigational and not available for commercial use.
    heel interessant maar we wisten het al; je hebt kennelijk iets gemist gisteren
  3. forum rang 6 Kaviaar 10 april 2024 16:14
    quote:

    Stork 49 schreef op 10 april 2024 16:08:

    [...]
    heel interessant maar we wisten het al; je hebt kennelijk iets gemist gisteren
    Goed nieuws kan men beter herhalen ;- )
  4. forum rang 5 Stork 49 11 april 2024 08:37
    quote:

    Kaviaar schreef op 10 april 2024 16:14:

    [...]

    Goed nieuws kan men beter herhalen ;- )
    helemaal waar, valt niets tegenin te brengen
  5. Renno54 11 april 2024 17:13
    Vrijdag, maandag, dinsdag of woensdag a.s. kan er belangrijk bericht komen van FDA betreffende de goedkeuring van de de Novo aanvraag.
  6. forum rang 6 Kaviaar 11 april 2024 18:49
    ONWARD® Medical Announces Publication of Full Year 2023
    Financial Results and Business Update Webcast

    EINDHOVEN, the Netherlands — April 11, 2024 — ONWARD Medical N.V. (Euronext: ONWD),
    the medical technology company creating innovative spinal cord stimulation therapies to restore
    movement, function, and independence in people with spinal cord injury (SCI), today announces
    that it will publish Full Year 2023 Financial Results and host a webcast to discuss business
    highlights.
    The webcast will be held on April 25, 2024, at 2:00PM CET / 08:00AM ET. It will be hosted by
    CEO Dave Marver and Interim CFO Khaled Bahi, who will discuss highlights from 2023 and
    provide a business update.

    ir.onwd.com/static-files/f5e9e0d4-54a...
  7. forum rang 5 Stork 49 16 april 2024 09:14
    quote:

    Blik dekkende afbijt schreef op 16 april 2024 09:10:

    Wanneer komen ze met je jaarcijfers?
    Ik dacht deze week.
    Die website van deze tent is de slechte die ik ooit in mijn leven ben tegengekomen.
    en jij bent d slechtste lezer als het gaat om bijdragen van anderen; daar vind je het het antwoord
  8. forum rang 4 biobert 16 april 2024 12:43
    quote:

    Dagobert Duck schreef op 16 april 2024 12:40:

    Onward behoort helaas wel weer bij de top drie van grootste dalers op de beurs vandaag!
    En dat zonder enige reden.
    Reden: de winst van Onward ligt verder in de toekomst en moet worden teruggerekend met de huidige stijgende rente. Het gevolg is dat de waarde van het aandeel daalt.
  9. forum rang 6 Kaviaar 16 april 2024 17:23
    quote:

    Dagobert Duck schreef op 16 april 2024 12:40:

    Onward behoort helaas wel weer bij de top drie van grootste dalers op de beurs vandaag!
    En dat zonder enige reden.
    Misschien kapers op de kust?
    Ik verwacht dat Onward t.z.t. van de FDA goedkeuring krijgt.
    Dan is er enorme potentie voor de producten van Onward.
    Als je de koers laag kan houden, dan kan je het bedrijf relatief goedkoop overnemen.
    Ik denk meer in die richting.
  10. forum rang 6 Kaviaar 16 april 2024 17:38
    Krijgen we nog te zien welke grootaandeelhouders meegedaan hebben met de emissie?
    Of hebben ze ervoor gezorgd dat het aantal gelijk gebleven is, door al bestaande aandelen te verkopen zodat hun belang gelijk blijft?
  11. VBR 17 april 2024 09:05
    quote:

    Kaviaar schreef op 16 april 2024 17:38:

    Krijgen we nog te zien welke grootaandeelhouders meegedaan hebben met de emissie?
    Of hebben ze ervoor gezorgd dat het aantal gelijk gebleven is, door al bestaande aandelen te verkopen zodat hun belang gelijk blijft?
    ir.onwd.com/static-files/6715816c-f96...

    "Existing shareholders participated in the deal with an aggregate of 333,333 shares and 333,333
    shares respectively allocated to INKEF Capital and EQT Life Sciences. Following the Offerings,
    INKEF Capital and EQT Life Sciences will respectively hold 11.5% and 11.2% of the Company’s
    share capital. An aggregate of 246,555 shares were also allocated to the following
    management, founders, and members of the Board of Directors of the Company: Dave Marver,
    CEO; Robert Odell, VP Operations; Lorenzo Fanti, VP Legal; Co-Founders Jocelyne Bloch and
    Grégoire Courtine, CSO; and Directors Ian Curtis, Kristina Dziekan, and Fred Colen."
  12. h980577. 17 april 2024 19:24
    quote:

    VBR schreef op 17 april 2024 09:05:

    [...]

    ir.onwd.com/static-files/6715816c-f96...

    "Existing shareholders participated in the deal with an aggregate of 333,333 shares and 333,333
    shares respectively allocated to INKEF Capital and EQT Life Sciences. Following the Offerings,
    INKEF Capital and EQT Life Sciences will respectively hold 11.5% and 11.2% of the Company’s
    share capital. An aggregate of 246,555 shares were also allocated to the following
    management, founders, and members of the Board of Directors of the Company: Dave Marver,
    CEO; Robert Odell, VP Operations; Lorenzo Fanti, VP Legal; Co-Founders Jocelyne Bloch and
    Grégoire Courtine, CSO; and Directors Ian Curtis, Kristina Dziekan, and Fred Colen."
    Op de site van Gimv zie ik niets over deze kapitaalronde. Zullen dus waarschijnlijk ook niet hebben meegedaan, bovenstaande ook lezende waar Gimv ook niet wordt genoemd.
  13. Renno54 19 april 2024 23:16
    Onderstaand stukje gekopieerd uit LinkedIn. Van ongeveer een week geleden. Had dit op het forum nog niet gezien.

    Today is World Parkinson’s Day, which is an opportunity to raise awareness about Parkinson’s disease (PD), a complex, progressive disease that affects the nervous system. We honor those who struggle with the disease and their caregivers. We also salute those working to advance research to find a cure for Parkinson’s disease.

    We are grateful for our partnership with The Michael J. Fox Foundation for Parkinson's Research (MJFF) in furthering our work in this field and learning more about how our therapies might address some of the symptoms related to PD. Because PD can cause tremor, slowness, stiffness, and walking and balance problems, it is called a “movement disorder,” according to MJFF.

    Last fall, we announced the publication of a Nature Medicine article highlighting the use of our investigational ARC Therapy™ to address gait challenges related to Parkinson’s disease. The study participant described in the Nature Medicine publication has been living with Parkinson’s disease for nearly three decades. He has a severe gait disorder that has not responded to conventional therapies. After the introduction of ARC Therapy and benefitting from a few weeks of rehabilitation, the study participant was able to walk without previously noticeable gait interruptions.

    Our research partner .NeuroRestore was awarded a $1 million grant from MJFF to study the effect of our ARC Therapy in six additional participants with Parkinson’s disease. We look forward to continuing to learn about the potential for the same technology platform and therapy we are developing for spinal cord injury to also address mobility challenges stemming from Parkinson’s disease.
    On this day of awareness, we appreciate the chance to collaborate with those in the field to work towards innovative solutions.

    *All ONWARD Medical devices and therapies, including but not limited to ARC-IM®, ARC-EX®, ARC-BCI™, and ARC Therapy™, alone or in combination with a brain-computer interface (BCI), are investigational and not available for commercial use.
  14. forum rang 6 Kaviaar 20 april 2024 08:37
    Bedankt Renno54. Wereldwijd zijn er 10 miljoen mensen die de ziekte Parkinson hebben. Als Onward een deel kan helpen met hun producten, dan zou dat voor deze mensen geweldig zijn. En dat door een NL bedrijf.

    www.parkinsonnet.nl/parkinson/#:~:tex...,is%20voor%20geen%20mens%20hetzelfde.
2.169 Posts
Pagina: «« 1 ... 60 61 62 63 64 ... 109 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.078
AB InBev 2 5.522
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.756
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 267
Accsys Technologies 23 10.755
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 191
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.754
Aedifica 3 919
Aegon 3.258 322.906
AFC Ajax 538 7.088
Affimed NV 2 6.297
ageas 5.844 109.895
Agfa-Gevaert 14 2.051
Ahold 3.538 74.342
Air France - KLM 1.025 35.091
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.042
Alfen 16 24.949
Allfunds Group 4 1.503
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 406
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.823
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.418
AMG 971 133.785
AMS 3 73
Amsterdam Commodities 305 6.697
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 491
Antonov 22.632 153.605
Aperam 92 15.017
Apollo Alternative Assets 1 17
Apple 5 383
Arcadis 252 8.786
Arcelor Mittal 2.034 320.778
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.326
Aroundtown SA 1 219
Arrowhead Research 5 9.745
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.343
ASML 1.766 108.309
ASR Nederland 21 4.502
ATAI Life Sciences 1 7
Atenor Group 1 516
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.688
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.404

Macro & Bedrijfsagenda

  1. 04 maart

    1. Nedap Q4-cijfers
    2. TKH Q4-cijfers
    3. Recticel Q4-cijfers
    4. Allfunds Q4-cijfers
    5. Werkloosheid januari (eur)
    6. Best Buy Q4-cijfers
    7. Pharming - Bava
    8. Atenor Q4-cijfers
  2. 05 maart

    1. Inkoopmanagersindex diensten februari def. (Jap)
    2. Inkoopmanagersindex diensten Caixin februari (Chi)
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht